Update on the management of inflammatory breast cancer
Update on the management of inflammatory breast cancer
复制标题
DOI：
10.1634/theoncologist.8-2-141
复制
发表时间：
2003-01-01
期刊：
影响因子：
5.8
通讯作者：
Hortobägyi, GN
中科院分区：
文献类型：
--
作者：
Cristofanilli, M;Buzdar, AU;Hortobägyi, GN
炎症性乳腺癌（IBC）是原发性乳腺癌最具侵袭性的表现，具有快速增殖的临床和生物学特征。在过去的30年里，IBC的多学科管理发生了变化，目前有明确的顺序概述，术前或新辅助化疗是主要的治疗方法。蒽环类药物和紫杉烷类药物是原发性乳腺癌治疗中最有效的细胞毒性药物，应成为IBC妇女治疗的标准药物。局部治疗包括伴或不伴手术的放射治疗，并在适当的药物治疗后继续发挥主要作用。对IBC发展的特定分子决定因素的许多研究提供了几个有趣的新治疗靶点。包括血管生成调节剂、法尼基转移酶抑制剂和p53调节剂在内的联合治疗方案在IBC的医疗管理中具有很大的前景。未来的治疗方法应该集中在这些发现上，这样我们就可以改善IBC妇女的整体预后。
Inflammatory breast cancer (IBC) is the most aggressive manifestation of primary breast carcinoma, with the clinical and biological characteristics of a rapidly proliferating disease. The multidisciplinary management of IBC has changed in the past 3 decades and is presently clearly outlined in sequence, with preoperative or neoadjuvant chemotherapy representing the mainstay of treatment. Anthracyclines and taxanes are the most effective cytotoxic agents in the management of primary breast cancer and should be the standard of treatment for women with IBC. Locoregional treatment includes radiotherapy with or without surgery and continues to play a major role after appropriate medical treatment. The many investigations into the particular molecular determinants of IBC development have provided several interesting new therapeutic targets. Combination regimens that include angiogenic modulators, farnesyl transferase inhibitors, and p53 modulators hold great promise in the medical management of IBC. Future therapeutic approaches should focus on these discoveries so that we can improve the overall prognosis for women with IBC.